NextDocs Corporation, a provider of Microsoft SharePoint-based compliance solutions for the life sciences industry, announced the launch of Trial Exchange, its newest product available on the NextDocs platform. Trial Exchange provides a consumer-style interface for investigators and site staff to access and contribute essential documents for clinical trials. As documents are uploaded through Trial Exchange, the documents enter workflows within the existing NextDocs eTMF module.
“NextDocs’ clinical product line is focused on delivering new innovations to the market. eTMF addressed the internal and partner collaboration challenges and now, with Trial Exchange, we’re enabling trial site staff to participate directly in the process,” explained Matt Walz, CTO at NextDocs. “Trial Exchange does not require training. It has a user experience that feels very consumer, but on the back-end, it is enterprise software and integrates seamlessly with eTMF and other clinical systems.”
Trial Exchange aims to address the challenges that life sciences companies face in managing clinical documents. It hopes to allow trial site staff to contribute documents to an established eTMF work stream, receive and complete tasks generated by the sponsor, view document statuses, and retrieve documents on demand. Trial Exchange is designed to reduce the time and cost of trial management, improve collaboration with investigators, and strengthen document security and compliance.
This new clinical portal allows life sciences companies to:
Trial Exchange provides a streamlined interface for investigators that clinical site staff can use with little to no training. Unlike many existing clinical portals, it plugs directly into the eTMF without additional routing, thus applying the Sponsor/CRO quality and document management processes to clincial site documents.
For more information on Trial Exchange or to register for an upcoming demo of our clinical document management solution, visit www.trialexchange.com.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.